iRadimed Corporation (NASDAQ: IRMD) reported record full‑year 2025 results, with revenue reaching $83.8 million and net income of $22.5 million. Non‑GAAP diluted earnings per share (EPS) for the year were $1.93, up 17 % from $1.66 in 2024, while non‑GAAP Q4 EPS rose to $0.54 from $0.44. The company also increased its regular quarterly cash dividend to $0.20 per share, up from $0.17, marking the first dividend change since its inception.
The record revenue streak continued with the company posting its eighteenth consecutive quarter of record sales. Growth was driven by strong demand for its MRI‑compatible infusion pumps and patient monitoring systems, with the new Orlando manufacturing facility expanding production capacity. The launch of the next‑generation MRidium 3870 IV pump in Q4 2025 added a high‑margin product to the portfolio, contributing to the revenue surge and setting the stage for accelerated sales in 2026.
iRadimed’s earnings beat analyst expectations by $0.05 per share, a 10 % overrun of the consensus estimate of $0.49 for Q4. The beat was largely a result of disciplined cost management and a favorable product mix that increased the proportion of high‑margin IV pumps. GAAP diluted EPS for the year was $1.75 and for Q4 was $0.50, both below the non‑GAAP figures but still above the 2024 GAAP EPS of $1.50 and Q4 2024 GAAP EPS of $0.40, respectively. The company’s gross margin of 77 % reflects strong pricing power and efficient manufacturing.
Management reiterated its 2026 outlook, projecting full‑year revenue of $91.0 million to $96.0 million and GAAP diluted EPS of $1.90 to $2.05. The guidance reflects confidence in the continued adoption of the MRidium 3870, which is expected to drive a significant revenue lift in the second half of 2026. The company also highlighted its debt‑free balance sheet and robust cash‑flow generation, which support the dividend increase and future capital allocation flexibility.
CEO Roger Susi said, “We remain focused on innovation, operational efficiency, and delivering strong returns to shareholders. The record revenue streak and the successful launch of the MRidium 3870 demonstrate our execution capability and reinforce our leadership in the MRI‑compatible device market.” Investors responded positively to the results, citing the earnings beat, dividend hike, and optimistic guidance as key drivers of the favorable market reaction.
The combination of high gross margins, a growing product pipeline, and a debt‑free balance sheet positions iRadimed for continued expansion. The company’s ability to scale production at the new Orlando facility while maintaining pricing power suggests resilience against supply‑chain headwinds and competitive pressures. With the MRidium 3870 expected to become a major revenue driver, iRadimed’s trajectory points toward a $100 million revenue run‑rate in 2026, reinforcing its long‑term growth prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.